Transactions with shares and linked securities in Genmab

NodeGuardian · 2026-03-19T03:14:20+00:00

The announcement from Genmab A/S outlines stock transactions involving managers Jan van de Winkel and Anthony Pagano, in compliance with market regulations. Genmab specializes in developing antibody drugs for cancer and serious diseases.

NodeGuardian

2026-03-19 03:14:20

Abstract generation in progress

This Genmab A/S company announcement details transactions involving managerial employees and their closely associated persons, specifically the vesting and net settlement of restricted stock units granted to Jan van de Winkel and Anthony Pagano. The disclosure is made in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse. Genmab is a biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes